RecruitingPhase 4NCT07811518

Latent Infection Freshmen Tracking for Tuberculosis

Real-World Implementation and Effectiveness of Tuberculosis Preventive Treatment in School Health Services in China


Sponsor

Affiliated Hospital of Nantong University

Enrollment

3,000 participants

Start Date

Aug 15, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this study is to learn whether taking short-course preventive treatment in high school and college freshmen with strong positive tuberculosis (TB) skin tests can safely and effectively protect them from developing active TB over a 3-to-4-years period. Main question: Does taking short-course preventive treatment reduce the risk of active TB in freshmen who have strong positive TB skin tests? All freshmen across 26 schools in Meishan City, Sichuan Province, China were screened for TB. Among them, the students with strong positive skin tests (indicating latent TB infection) and no active disease entered the study. Students voluntarily chose to either take a 3-month short-course preventive treatment under campus medical supervision or receive routine health observation without medication. Researchers tracked all participants for 3 to 4 years to monitor who developed active TB and evaluate the treatment's safety and effectiveness.


Eligibility

Min Age: 14 YearsMax Age: 24 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called tuberculosis preventive treatment for people with latent tuberculosis infection (ltbi) and tuberculosis (tb). The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGtuberculosis preventive treatment

3HR Regimen: Isoniazid (INH) + Rifampin (RIF), once daily, 90 total doses (3 months); 3H2P2 Regimen: Isoniazid (INH) + Rifapentine (RPT), twice weekly, 24 total doses (3 months)


Locations(2)

Affiliated Hospital of Nantong University

Nantong, Jiangsu, China

Meishan Municipal Center for Disease Prevention and Control

Meishan, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07811518


Related Trials